In addition, loss of MMR protein expression and MSI analyses have gained increased clinical interest during recent years, as these biomarkers were approved by the American Food and Drug Administration (FDA) in 2017 to guide immunotherapy with pembrolizumab across tumor types (5, 6). The gene discussed is MRC1; the disease is neoplasm.